Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02557971 · ClinicalTrials.gov registry record
Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 315
- Enrollment target
NCT02557971: Completed study, sponsored by Allergan.
NCT02557971 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 315 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02557971 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 315 participants
- Enrollment target
Study Summary
This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice. The study will determine the rate of post procedural urinary retention requiring catheterization and identify factors that may predict urinary retention.
Interventions
- DRUG onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-07 |
What the finished NCT02557971 record still lists
NCT02557971 is an observational study that tracks outcomes without assigning an intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which onabotulinumtoxinA is the first listed.
NCT02557971 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02557971 about?
NCT02557971 is a clinical study titled "Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder". This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice. The study will determine the rate of post procedural urinary retention requiring catheterization and identify factors that may predict urinary ...
What is the current status of trial NCT02557971?
This trial is currently completed. The enrollment target is 315 participants. The study started on 2015-08. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02557971?
The interventions under investigation include: onabotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT02557971?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia